Pilot Study in Pharmacogenomic Management of Empagliflozin in Type 2 Diabetes Mellitus Patients Publisher



Jamalizadeh M^{1, 2} ; Hasanzad M^{1, 3} ; Sarhangi N¹ ; Sharifi F⁴ ; Nasliesfahani E² ; Larijani B⁵ Show Affiliations
Source: Journal of Diabetes and Metabolic Disorders Published:2021

Abstract

Background: Type 2 diabetes mellitus (T2DM) is a metabolic disorder in which the patients with high blood sugar develop insufficient insulin secretion or insulin resistance. The solute carrier family, 5 member 2 (SLC5A2) gene is a member of sodium/glucose transporter family which can reduce heart and kidney problems. The current study aims to look into any association between rs11646054 variant in SLC5A2 gene and the anti-diabetic efficacy and safety of empagliflozin. Methods: 14 T2DM who failed to respond to previous treatments, empagliflozin 10 mg was added for 6 months. Genotyping of the rs11646054 variant of SLC5A2 gene was performed by polymerase chain reaction (PCR) followed by Sanger sequencing. Results: Although hemoglobin A1c (HbA1c) and low-density lipoprotein (LDL) were not significantly different, but the mean fasting blood sugar (FBS), 2-h post prandial (2hpp), albumin-to-creatinine ratio (ACR), and total cholesterol (TC) were significantly decreased after 6 months empagliflozin treatment. There was a significant difference in the mean final reductions in FBS level among genotypes. It's important to mention that those who were GG homozygotes had a tendency to have more decrements. Conclusions: The study results indicate that effects of variation in SLC5A2 (rs11646054) on the clinical efficacy of empagliflozin were negligible. © 2021, Springer Nature Switzerland AG.